Bristol Myers Squibb to acquire Mirati Therapeutics in $4.8bn deal
Bristol Myers Squibb (NYSE: BMY) is set to acquire Mirati Therapeutics, Inc. (NASDAQ: MRTX) at $58.00 per share in a cash deal valued at $4.8 ... Read More
Eli Lilly announces $1.4bn acquisition of POINT Biopharma in radiopharmaceutical domain
Eli Lilly and Company (NYSE: LLY) is set to acquire POINT Biopharma Global, Inc. (NASDAQ: PNT), a leading radiopharmaceutical firm, marking a significant leap in ... Read More
Viatris Inc. announces divestitures in key business sectors: Comprehensive breakdown
Viatris Inc. (NASDAQ: VTRS), a frontrunner in global healthcare, has unveiled a series of divestitures in its business framework. Leading the announcements, Viatris is set ... Read More
Bausch + Lomb completes XIIDRA acquisition to fortify dry eye offering
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a prominent global eye health company, has successfully wrapped up its acquisition of XIIDRA (lifitegrast ophthalmic solution) 5%. XIIDRA ... Read More
Advent International completes majority acquisition of Suven Pharma
Advent International, a global private equity giant, proudly announces the successful completion of its majority acquisition of Suven Pharma, a renowned Contract Development and Manufacturing ... Read More
Ind-Swift Labs to sell API and CRAMS business to Synthimed for Rs 1,650cr
In a groundbreaking move that has left the pharmaceutical sector buzzing, the Board of Directors of Ind-Swift Laboratories Limited ("Ind-Swift") announced the blockbuster sale of ... Read More
Cipla to acquire Actor Pharma to dominate South African OTC market
In a strategic move that amplifies its commitment to the Over-The-Counter (OTC) business, Cipla South Africa, a 100% owned subsidiary of Cipla Limited (BSE: 500087; ... Read More
Novo Nordisk acquires Embark Biotech and enters R&D collaboration to advance obesity treatments
Novo Nordisk, a global leader in healthcare, has acquired Embark Biotech, including its lead metabolic program, in a deal that further strengthens its portfolio in ... Read More
Lilly expands portfolio with $1.9bn acquisition of Versanis Bio
In a move marking a significant expansion in the biopharmaceutical sector, Eli Lilly and Company (Lilly) has successfully completed the acquisition of Versanis Bio, a ... Read More
Lilly wraps up Sigilon Therapeutics acquisition to amplify Type 1 diabetes research
Eli Lilly and Company (Lilly) has formally announced the culmination of its $309.6 million takeover of biopharma trailblazer, Sigilon Therapeutics, Inc. (NASDAQ: SGTX). This strategic ... Read More